{
    "root": "3000f004-710e-edc2-e063-6294a90a86ce",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Escitalopram",
    "value": "20250310",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ESCITALOPRAM OXALATE",
            "code": "5U85DBW7LO"
        }
    ],
    "indications": "escitalopram indicated treatment : major depressive disorder ( mdd ) adults pediatric patients 12 years age older . generalized anxiety disorder ( gad ) adults . additional pediatric information approved abbvie inc. \u2019 lexapro ( escitalopram ) tablets lexapro ( escitalopram ) oral solution . however , due abbvie inc. \u2019 marketing exclusivity rights , product labeled information .",
    "contraindications": "indication population recommended mdd adults ( 2.1 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily mdd pediatric patients 12 years older ( 2.1 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily gad adults ( 2.2 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily additional benefits seen 20 mg daily ( 2.1 ) administer daily , morning evening , without food ( 2.3 ) elderly patients : recommended 10 mg daily ( 2.4 ) hepatic impairment : recommended 10 mg daily ( 2.4 , 8.6 ) discontinuing escitalopram tablets , reduce dose gradually whenever possible ( 2.5 )",
    "warningsAndPrecautions": "escitalopram tablets , usp,20 mg round , white off-white , biconvex , film coated tablets , debossed `` p 20 `` scored side plain side . supplied ndc : 70518-2317-00 ndc : 70518-2317-01 ndc : 70518-2317-02 ndc : 70518-2317-03 packaging : 30 1 bottle plastic packaging : 30 1 blister pack packaging : 90 1 bottle plastic packaging : 90 1 bottle plastic store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "escitalopram tablets contraindicated patients : taking maois escitalopram tablets within 14 days stopping treatment escitalopram tablets increased risk serotonin syndrome . escitalopram tablets within 14 days stopping maoi intended treat psychiatric disorders also contraindicated [ ( 2.7 ) ( 5.2 ) ] . starting escitalopram tablets patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.6 ) ( 5.2 ) ] . taking pimozide [ ( 7 ) ] . hypersensitivity escitalopram citalopram inactive ingredients escitalopram tablets .",
    "indications_original": "Escitalopram is indicated for the treatment of:\n                  \n                     major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older.\n                     generalized anxiety disorder (GAD) in adults.\n                  \n                  \n                     Additional pediatric use information is approved for AbbVie Inc.\u2019s LEXAPRO (escitalopram) tablets and LEXAPRO (escitalopram) oral solution. However, due to AbbVie Inc.\u2019s marketing exclusivity rights, this drug product is not labeled with that information.",
    "contraindications_original": "Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram tablets, reduce dose gradually whenever possible ( 2.5 )",
    "warningsAndPrecautions_original": "Escitalopram Tablets, USP,20 mg\u00a0are round, white to off-white, biconvex, film coated tablets, debossed with \"P 20\" on the scored side and plain on the other side. They are supplied in\n                  NDC: 70518-2317-00\n                  NDC: 70518-2317-01\n                  NDC: 70518-2317-02\n                  NDC: 70518-2317-03\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F).\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Escitalopram tablets are contraindicated in patients:\n                  \n                     taking MAOIs with escitalopram tablets or within 14 days of stopping treatment with escitalopram tablets because of an increased risk of serotonin syndrome. The use of escitalopram tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated\n  \n   [see Dosage and Administration (\n   \n    2.7) and Warnings and Precautions (\n   \n    5.2)]\n  \n   . Starting escitalopram tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome\n  \n   [see Dosage and Administration (\n   \n    2.6) and Warnings and Precautions (\n   \n    5.2)]\n  \n   .\n \n  \n                     taking pimozide\n  \n   [see Drug Interactions (\n   \n    7)]\n  \n   .\n \n  \n                     with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in escitalopram tablets."
}